Investigational Treatment of Congenital Hypogonadotropic Hypogonadism in Infants
Hormone and Metabolic Research · 01.01.2025 · 57 (01) · 18-24
DOI: 10.1055/a-2343-4696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.01.2025. Verfasst von Xiaoya Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health,…. Hauptthemen laut MEDLINE: Hypogonadism, Gonadotropin-Releasing Hormone, Chorionic Gonadotropin, Menotropins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
The aim of the study was to investigate whether the administration of gonadotropins to mimic the physiological development of infants with congenital hypogonadotropic hypogonadism (CHH) after birth can facilitate testicular descent, penile growth, and ultimately preserve fertility. This study included eight infants with CHH who received a gonadotropin-releasing hormone (GnRH) pump or human chorionic gonadotropin (HCG) combined with human menopausal gonadotropin (HMG) therapy at Beijing Children's Hospital from August 2018 to March 2023. The age of the infants ranged from 6 months to 2 years. 2. For literature review, a search was conducted in the PubMed database using the keywords “congenital hypogonadotropic hypogonadism,” “infants,” and “mini-puberty” up until June 2023. After 1–3 months of treatment, significant increases were observed in PL and TV. The testes descended from the inguinal region to the scrotum. Serum T and INH-B levels increased from being undetectable to 737.1±409.5 ng/dl and from 47.88±23.03 to 168.94±59.34 pg/ml, respectively. In a comparative literature review of 22 infants with CHH, the age at treatment initiation ranged from 0.5 to 7.9 months. Treatment involved various dosages and durations, ranging from 2 to 6 months of subcutaneous injections of LH and FSH. Both therapies successfully improved PL, TV, and testicular descent; reduced the need for surgery; and were safe. This is the first report of the use of a GnRH pump for the treatment of infant CHH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zitieren
APA
Ren, X., Wang, Y., Liu, Y., & Gong, C. (2025). Investigational Treatment of Congenital Hypogonadotropic Hypogonadism in Infants. Hormone and Metabolic Research, 57(01), 18-24. https://doi.org/10.1055/a-2343-4696
Vancouver
Ren X, Wang Y, Liu Y, Gong C. Investigational Treatment of Congenital Hypogonadotropic Hypogonadism in Infants. Hormone and Metabolic Research. 2025;57(01):18-24. doi:10.1055/a-2343-4696
BibTeX
@article{Ren2025,
author = {Ren, Xiaoya and Wang, Yi and Liu, Ying and Gong, Chunxiu},
title = {Investigational Treatment of Congenital Hypogonadotropic Hypogonadism in Infants},
journal = {Hormone and Metabolic Research},
year = {2025},
volume = {57},
number = {01},
pages = {18--24},
doi = {10.1055/a-2343-4696}
}
EUVIMED